Understanding machine learning classifier decisions in automated radiotherapy quality assurance.

Journal: Physics in medicine and biology
Published Date:

Abstract

The complexity of generating radiotherapy treatments demands a rigorous quality assurance (QA) process to ensure patient safety and to avoid clinically significant errors. Machine learning classifiers have been explored to augment the scope and efficiency of the traditional radiotherapy treatment planning QA process. However, one important gap in relying on classifiers for QA of radiotherapy treatment plans is the lack of understanding behind a specific classifier prediction. We develop explanation methods to understand the decisions of two automated QA classifiers: (1) a region of interest (ROI) segmentation/labeling classifier, and (2) a treatment plan acceptance classifier. For each classifier, a local interpretable model-agnostic explanation (LIME) framework and a novel adaption of team-based Shapley values framework are constructed. We test these methods in datasets for two radiotherapy treatment sites (prostate and breast), and demonstrate the importance of evaluating QA classifiers using interpretable machine learning approaches. We additionally develop a notion of explanation consistency to assess classifier performance. Our explanation method allows for easy visualization and human expert assessment of classifier decisions in radiotherapy QA. Notably, we find that our team-based Shapley approach is more consistent than LIME. The ability to explain and validate automated decision-making is critical in medical treatments. This analysis allows us to conclude that both QA classifiers are moderately trustworthy and can be used to confirm expert decisions, though the current QA classifiers should not be viewed as a replacement for the human QA process.

Authors

  • Yunsheng Chen
    Department of Mechanical & Industrial Engineering, University of Toronto, Toronto, Ontario M5S 3G8, Canada.
  • Dionne M Aleman
    Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, Ontario M5S 3G8, Canada.
  • Thomas G Purdie
    Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario M5S 3E2, Canada; and Techna Institute, University Health Network, Toronto, Ontario M5G 1P5, Canada.
  • Chris McIntosh